Developer docs
API playgroundTry for free, no card

Search company profiles

Grace Science Foundation

Full company profile

uuid000mo4p

Namestring
Grace Science Foundation
Legal namestring
Grace Science Foundation
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Grace Science Foundation is a private nonprofit research foundation founded in 2013 in San Francisco by Matt and Kristen Wilsey after their daughter Grace was diagnosed with NGLY1 Deficiency, an ultra-rare genetic disorder. The foundation's mission is to coordinate and fund research aimed at curing NGLY1 Deficiency, an endeavor that traditional biomedical funding mechanisms have neglected due to the disease's extreme rarity — approximately 130 patients have been confirmed worldwide as of February 2024. The foundation operates as a patient-driven convening organization, building a global research network of 20+ teams and ~75 scientists across 20 medical centers in the USA, Canada, Germany, Italy, and Japan. Its core "products" are the NGLY1 Patient Registry, a family community platform, research grantmaking, and a translational for-profit affiliate — Grace Science, LLC — co-founded with Nobel Laureate Dr. Carolyn Bertozzi to convert academic discoveries into drug candidates.

The foundation's technology base is biomedical rather than digital: it supports research using iPS cell platforms (Gladstone/Dr. Yamanaka), glycan biochemistry (RIKEN/Dr. Suzuki), Drosophila and C. elegans models (Baylor, Harvard/MGH), mouse models (Jackson Laboratory), high-throughput genetic interaction mapping (University of Toronto), and stem cell biology (Salk, Stanford). The foundation channels donations into these academic collaborations and into the Takeda T-CiRA industrial drug discovery program, with no commercial revenue of its own. The 100%-of-donations-to-research commitment is a primary donor acquisition claim, marketed through patient stories, blog content, earned media in Wired, Nature, The New Yorker, CNN, and Stanford, and community events such as 'Run Across Tennessee.'

Revenue is entirely donation-based and not publicly disclosed. The foundation is led by Chairman/President/Co-founder Matt Wilsey, a Stanford-educated entrepreneur and former KKR and CardSpring executive; Co-founder Kristen Wilsey; Chief Scientific Officer Kevin Lee; and Clinical Research & Patient Support Manager Gracie Morrison. The organization is structurally a patient advocacy foundation with a translational for-profit arm, positioning it at the intersection of nonprofit research coordination and venture-style drug development.

Short descriptiontext

Grace Science Foundation is a San Francisco-based nonprofit founded in 2013 that funds and coordinates a global research network of 20+ teams to develop treatments for NGLY1 Deficiency, an ultra-rare genetic disorder affecting approximately 130 patients worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease research, genetic disorder research, patient registry services, medical research funding, drug development coordination
Industry3 codes
PRIMARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Research Foundation
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Charitable Contributions
TypeGrants Donations
Description

The foundation is funded entirely through donations, with 100% of donations going directly to finding a cure for NGLY1 Deficiency. No commercial revenue streams.

gracescience.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Grace Science Foundation is a nonprofit medical research foundation that coordinates and funds a global research network of scientists and clinicians to find treatments and a cure for NGLY1 Deficiency, an ultra-rare genetic disorder. It operates an NGLY1 Patient Registry and natural history study, supports roughly 75 scientists across 20 medical centers in 5 countries, and bridges basic discovery to therapeutic development via a translational entity (Grace Science LLC) co-founded with Nobel Laureate Dr. Carolyn Bertozzi. The foundation is funded entirely through donations, with a stated commitment that 100% of contributions go directly to research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 130 patients diagnosed and in registry as of February 2024
+2 more records
Product overview1 text field

Grace Science Foundation operates as a research-focused nonprofit organization rather than a traditional software company. Its primary offerings include: (1) an NGLY1 Patient Registry that collects patient data for clinical research; (2) Research Coordination Services funding over 20 research teams globally; (3) an NGLY1 Family Community Platform connecting patients and families; (4) Educational Resources and Blog providing disease and research information; and (5) a Donation Platform directing 100% of contributions to research. The foundation does not offer a unified software product but rather a constellation of programs supporting NGLY1 research and patient advocacy.

Product and service4 records
1NGLY1 Patient Registry
CategoryPatient Registry / Natural History Study
Description

A patient registry platform that collects and maintains longitudinal data from individuals diagnosed with NGLY1 Deficiency to support clinical research, natural history studies, and trial-readiness. Built for the global NGLY1 patient and family community (~130 confirmed patients worldwide as of February 2024).

2Research Coordination Services
CategoryResearch Funding and Coordination
Description

Coordination and direct funding of academic and industry research teams working on NGLY1 Deficiency biology, animal models, drug screening, and therapeutic development. The foundation has funded 20+ research teams at 20 medical centers in 5 countries (USA, Canada, Germany, Italy, Japan), supporting approximately 75 scientists.

3NGLY1 Family Community Platform
CategoryPatient and Family Community
Description

Community support platform connecting families affected by NGLY1 Deficiency, providing peer support, patient stories, family resources, and a sense of community for an ultra-rare disease population spread across multiple countries.

4Donation Platform
CategoryFundraising / Charitable Giving Platform
Description

Online donation portal enabling supporters to contribute directly to NGLY1 research funding, with itemized giving levels (e.g., $100 funds an RNA-Seq library preparation, $250 funds 10 western blot protein gels, $500 funds 2 antibodies). The foundation states that 100% of donations go directly to research with no overhead deduction.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership with Dr. Shinya Yamanaka (Nobel Laureate) and Dr. Deepak Srivastava. Dr. Yamanaka's iPS cell technology provides a platform for studying NGLY1 Deficiency using patient-derived cells. The Finkbeiner Lab collaborated on NGLY1 Deficiency phenotypes research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple research collaborations with Stanford labs including Bertozzi Lab (Dr. Carolyn Bertozzi, Nobel Laureate), Dr. Greg Enns (Biochemical Genetics), Dr. Katherine Mackenzie (Pediatric Neurology), Dr. Michael Snyder (Genetics), and Dr. Maria Grazia Roncarolo (Stem Cell Transplantation).

3RIKEN
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Glycometabolome Team at RIKEN led by Dr. Tadashi Suzuki. Research focuses on NGLY1 enzyme function, free-glycans analysis, and drug screening for ENGase inhibitors. Dr. Chengcheng Huang and Dr. Haruhiko Fujihira conduct research at RIKEN.

gracescience.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

T-CiRA is a joint program of Takeda, CiRA, and RIKEN. Dr. Ryuichi Tozawa, Dr. Takayuki Kamei, and Dr. Makoto Asahina work on NGLY1 research through this partnership, focusing on drug discovery and therapeutic development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Dr. Hamed Jafar-Nejad using Drosophila models to understand NGLY1's role in animal development and identify drug targets. Dr. Ashutosh Pandey also conducts research at BCM.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Gary Ruvkun's lab conducts research on protein degradation mechanisms and NGLY1's role. Dr. Nicolas Lehrbach studies genetic modifiers of proteasome function in NGLY1 mutant C. elegans models.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Nan Yan's lab investigates innate immune responses associated with NGLY1 deficiency. Dr. Kun Yang characterizes immune phenotypes and explores therapeutic mechanisms.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Senthil Radhakrishnan's lab studies cellular protein degradation pathways with focus on the Nrf1-proteasome axis and translates findings into therapies for NGLY1 disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mouse model development for human neuromuscular diseases. Dr. Orsolya Kiraly develops and optimizes mice models for NGLY1 research. Dr. Lorin Roiphe contributes genetics expertise.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Charlie Boone's lab conducts high-throughput systems level genetic analyses and genetic interaction network mapping relevant to NGLY1 research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Rusty Gage's lab models human neurological disease using stem cells and studies genomic mosaicism relevant to NGLY1 Deficiency research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Translational entity co-founded by Matt Wilsey and Nobel Laureate Dr. Carolyn Bertozzi to translate scientific discoveries into real-world treatments, bridging the gap between discovery and patient access.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Family-driven rare disease foundation that funded research leading to FDA-approved spinal muscular atrophy therapies (Spinraza, Zolgensma, Evrysdi). Direct peer for Grace Science given shared ultra-rare pediatric genetic disease model and proven pipeline-to-treatment track record.

TypeBroad incumbent
Description

Advocacy and support organization for the broader rare disease community, providing resources, networking, and educational content across many conditions. Functionally comparable to Grace Science in rare disease community-building and awareness, though operates as an umbrella rather than single-disease funder.

3Chordoma Foundation
TypeDirect peer
Description

Patient-founded foundation funding and coordinating research for an ultra-rare cancer, including translational research programs and partnerships with academic medical centers. Structurally similar to Grace Science in coordinating fragmented research for a low-prevalence disease.

TypeBroad incumbent
Description

Large disease-focused foundation that funded foundational CF research and partnered with Vertex to develop transformative therapies, generating substantial royalty revenues. A scaled-up version of Grace Science's intended research-to-treatment translation model, though operating at far greater scale and financial footprint.

TypeEmerging player
Description

Nonprofit data platform focused on building federated patient registries for rare diseases. Comparable to Grace Science's patient registry initiative but operates as an infrastructure platform across many conditions rather than for a single disease.

TypeDirect peer
Description

Patient-driven nonprofit funding Duchenne muscular dystrophy research globally, with parallel translational and advocacy operations. Highly comparable to Grace Science in mission, structure, and operating model for ultra-rare genetic disease research coordination.

TypeDirect peer
Description

Pediatric cancer research foundation funding research grants and clinical trials. Comparable to Grace Science in philanthropic fundraising model, research coordination, and pediatric disease focus, though operating at substantially greater scale and a longer funding history.

TypeBroad incumbent
Description

Umbrella advocacy organization for rare diseases in the US, providing patient assistance programs and policy advocacy. Comparable in rare disease mission space and policy influence but operates across many conditions rather than a single disease.

TypeDirect peer
Description

Parent-led foundation funding research to cure Sanfilippo Syndrome, an ultra-rare pediatric genetic disorder. Comparable to Grace Science in mission, scale, parent-driven origin story, and direct research funding approach.

TypeDirect peer
Description

Family-driven rare disease research foundation funding therapeutic development for Prader-Willi syndrome. Highly comparable to Grace Science in ultra-rare genetic disease focus, parent-led origin, and research grant-making operating model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grace Science Foundation

Rare Disease Research Foundationgracescience.org

Grace Science Foundation is a San Francisco-based nonprofit founded in 2013 that funds and coordinates a global research network of 20+ teams to develop treatments for NGLY1 Deficiency, an ultra-rare genetic disorder affecting approximately 130 patients worldwide.

What Grace Science Foundation does

Grace Science Foundation is a private nonprofit research foundation founded in 2013 in San Francisco by Matt and Kristen Wilsey after their daughter Grace was diagnosed with NGLY1 Deficiency, an ultra-rare genetic disorder. The foundation's mission is to coordinate and fund research aimed at curing NGLY1 Deficiency, an endeavor that traditional biomedical funding mechanisms have neglected due to the disease's extreme rarity — approximately 130 patients have been confirmed worldwide as of February 2024. The foundation operates as a patient-driven convening organization, building a global research network of 20+ teams and ~75 scientists across 20 medical centers in the USA, Canada, Germany, Italy, and Japan. Its core "products" are the NGLY1 Patient Registry, a family community platform, research grantmaking, and a translational for-profit affiliate — Grace Science, LLC — co-founded with Nobel Laureate Dr. Carolyn Bertozzi to convert academic discoveries into drug candidates.

The foundation's technology base is biomedical rather than digital: it supports research using iPS cell platforms (Gladstone/Dr. Yamanaka), glycan biochemistry (RIKEN/Dr. Suzuki), Drosophila and C. elegans models (Baylor, Harvard/MGH), mouse models (Jackson Laboratory), high-throughput genetic interaction mapping (University of Toronto), and stem cell biology (Salk, Stanford). The foundation channels donations into these academic collaborations and into the Takeda T-CiRA industrial drug discovery program, with no commercial revenue of its own. The 100%-of-donations-to-research commitment is a primary donor acquisition claim, marketed through patient stories, blog content, earned media in Wired, Nature, The New Yorker, CNN, and Stanford, and community events such as 'Run Across Tennessee.'

Revenue is entirely donation-based and not publicly disclosed. The foundation is led by Chairman/President/Co-founder Matt Wilsey, a Stanford-educated entrepreneur and former KKR and CardSpring executive; Co-founder Kristen Wilsey; Chief Scientific Officer Kevin Lee; and Clinical Research & Patient Support Manager Gracie Morrison. The organization is structurally a patient advocacy foundation with a translational for-profit arm, positioning it at the intersection of nonprofit research coordination and venture-style drug development.

Grace Science Foundation firmographics

Firmographics
Name
Grace Science Foundation
Legal name
Grace Science Foundation
Website
https://gracescience.org
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Grace Science Foundation is a San Francisco-based nonprofit founded in 2013 that funds and coordinates a global research network of 20+ teams to develop treatments for NGLY1 Deficiency, an ultra-rare genetic disorder affecting approximately 130 patients worldwide.
Ownership category
akta.pro rank

Grace Science Foundation industry classification

Industry
Product category
Rare Disease Research Foundation
NAICS
Scientific Research and Development Services (5417), Voluntary Health Organizations (813212)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAGAKAI
Research & Science Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Rare disease research
  • Genetic disorder research
  • Patient registry services
  • Medical research funding
  • Drug development coordination

Where Grace Science Foundation is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Grace Science Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Technology or R&D, Personnel

Revenue model

  1. Donations and Charitable Contributions: The foundation is funded entirely through donations, with 100% of donations going directly to finding a cure for NGLY1 Deficiency. No commercial revenue streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Grace Science Foundation product offering

Product offering

Core offering

Grace Science Foundation is a nonprofit medical research foundation that coordinates and funds a global research network of scientists and clinicians to find treatments and a cure for NGLY1 Deficiency, an ultra-rare genetic disorder. It operates an NGLY1 Patient Registry and natural history study, supports roughly 75 scientists across 20 medical centers in 5 countries, and bridges basic discovery to therapeutic development via a translational entity (Grace Science LLC) co-founded with Nobel Laureate Dr. Carolyn Bertozzi. The foundation is funded entirely through donations, with a stated commitment that 100% of contributions go directly to research.

Product overview

Grace Science Foundation operates as a research-focused nonprofit organization rather than a traditional software company. Its primary offerings include: (1) an NGLY1 Patient Registry that collects patient data for clinical research; (2) Research Coordination Services funding over 20 research teams globally; (3) an NGLY1 Family Community Platform connecting patients and families; (4) Educational Resources and Blog providing disease and research information; and (5) a Donation Platform directing 100% of contributions to research. The foundation does not offer a unified software product but rather a constellation of programs supporting NGLY1 research and patient advocacy.

Differentiator

Problem solved

Functional benefit

Products and services

  • NGLY1 Patient Registry A patient registry platform that collects and maintains longitudinal data from individuals diagnosed with NGLY1 Deficiency to support clinical research, natural history studies, and trial-readiness. Built for the global NGLY1 patient and family community (~130 confirmed patients worldwide as of February 2024).
  • Research Coordination Services Coordination and direct funding of academic and industry research teams working on NGLY1 Deficiency biology, animal models, drug screening, and therapeutic development. The foundation has funded 20+ research teams at 20 medical centers in 5 countries (USA, Canada, Germany, Italy, Japan), supporting approximately 75 scientists.
  • NGLY1 Family Community Platform Community support platform connecting families affected by NGLY1 Deficiency, providing peer support, patient stories, family resources, and a sense of community for an ultra-rare disease population spread across multiple countries.
  • Donation Platform Online donation portal enabling supporters to contribute directly to NGLY1 research funding, with itemized giving levels (e.g., $100 funds an RNA-Seq library preparation, $250 funds 10 western blot protein gels, $500 funds 2 antibodies). The foundation states that 100% of donations go directly to research with no overhead deduction.

Quantifiable outcome

  • 130 patients diagnosed and in registry as of February 2024
  • +2 more outcomes

Companies that use Grace Science Foundation

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Grace Science Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Grace Science Foundation partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core.

  • Gladstone InstitutescoreStrategic or Co-development PartnerAcademic research partnership with Dr. Shinya Yamanaka (Nobel Laureate) and Dr. Deepak Srivastava. Dr. Yamanaka's iPS cell technology provides a platform for studying NGLY1 Deficiency using patient-derived cells. The Finkbeiner Lab collaborated on NGLY1 Deficiency phenotypes research.
  • Stanford UniversitycoreStrategic or Co-development PartnerMultiple research collaborations with Stanford labs including Bertozzi Lab (Dr. Carolyn Bertozzi, Nobel Laureate), Dr. Greg Enns (Biochemical Genetics), Dr. Katherine Mackenzie (Pediatric Neurology), Dr. Michael Snyder (Genetics), and Dr. Maria Grazia Roncarolo (Stem Cell Transplantation).
  • RIKENcoreStrategic or Co-development PartnerCollaboration with Glycometabolome Team at RIKEN led by Dr. Tadashi Suzuki. Research focuses on NGLY1 enzyme function, free-glycans analysis, and drug screening for ENGase inhibitors. Dr. Chengcheng Huang and Dr. Haruhiko Fujihira conduct research at RIKEN.
  • Takeda Pharmaceutical (T-CiRA)coreStrategic or Co-development PartnerT-CiRA is a joint program of Takeda, CiRA, and RIKEN. Dr. Ryuichi Tozawa, Dr. Takayuki Kamei, and Dr. Makoto Asahina work on NGLY1 research through this partnership, focusing on drug discovery and therapeutic development.
  • Baylor College of MedicinecoreStrategic or Co-development PartnerResearch collaboration with Dr. Hamed Jafar-Nejad using Drosophila models to understand NGLY1's role in animal development and identify drug targets. Dr. Ashutosh Pandey also conducts research at BCM.
  • Massachusetts General Hospital (Harvard)coreStrategic or Co-development PartnerDr. Gary Ruvkun's lab conducts research on protein degradation mechanisms and NGLY1's role. Dr. Nicolas Lehrbach studies genetic modifiers of proteasome function in NGLY1 mutant C. elegans models.
  • UT Southwestern Medical CentercoreStrategic or Co-development PartnerDr. Nan Yan's lab investigates innate immune responses associated with NGLY1 deficiency. Dr. Kun Yang characterizes immune phenotypes and explores therapeutic mechanisms.
  • Virginia Commonwealth UniversitycoreStrategic or Co-development PartnerDr. Senthil Radhakrishnan's lab studies cellular protein degradation pathways with focus on the Nrf1-proteasome axis and translates findings into therapies for NGLY1 disease.
  • The Jackson LaboratorycoreStrategic or Co-development PartnerMouse model development for human neuromuscular diseases. Dr. Orsolya Kiraly develops and optimizes mice models for NGLY1 research. Dr. Lorin Roiphe contributes genetics expertise.
  • University of TorontocoreStrategic or Co-development PartnerDr. Charlie Boone's lab conducts high-throughput systems level genetic analyses and genetic interaction network mapping relevant to NGLY1 research.
  • Salk InstitutecoreStrategic or Co-development PartnerDr. Rusty Gage's lab models human neurological disease using stem cells and studies genomic mosaicism relevant to NGLY1 Deficiency research.
  • Grace Science LLCcoreStrategic or Co-development PartnerTranslational entity co-founded by Matt Wilsey and Nobel Laureate Dr. Carolyn Bertozzi to translate scientific discoveries into real-world treatments, bridging the gap between discovery and patient access.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Grace Science Foundation competitors and assessment

Company assessment

Direct peers

  • Cure SMA: Family-driven rare disease foundation that funded research leading to FDA-approved spinal muscular atrophy therapies (Spinraza, Zolgensma, Evrysdi). Direct peer for Grace Science given shared ultra-rare pediatric genetic disease model and proven pipeline-to-treatment track record.
  • Chordoma Foundation: Patient-founded foundation funding and coordinating research for an ultra-rare cancer, including translational research programs and partnerships with academic medical centers. Structurally similar to Grace Science in coordinating fragmented research for a low-prevalence disease.
  • Parent Project Muscular Dystrophy (PPMD): Patient-driven nonprofit funding Duchenne muscular dystrophy research globally, with parallel translational and advocacy operations. Highly comparable to Grace Science in mission, structure, and operating model for ultra-rare genetic disease research coordination.
  • Alex's Lemonade Stand Foundation: Pediatric cancer research foundation funding research grants and clinical trials. Comparable to Grace Science in philanthropic fundraising model, research coordination, and pediatric disease focus, though operating at substantially greater scale and a longer funding history.
  • cureSanfilippo Foundation: Parent-led foundation funding research to cure Sanfilippo Syndrome, an ultra-rare pediatric genetic disorder. Comparable to Grace Science in mission, scale, parent-driven origin story, and direct research funding approach.
  • Foundation for Prader-Willi Research: Family-driven rare disease research foundation funding therapeutic development for Prader-Willi syndrome. Highly comparable to Grace Science in ultra-rare genetic disease focus, parent-led origin, and research grant-making operating model.

Broad incumbents

  • Global Genes: Advocacy and support organization for the broader rare disease community, providing resources, networking, and educational content across many conditions. Functionally comparable to Grace Science in rare disease community-building and awareness, though operates as an umbrella rather than single-disease funder.
  • Cystic Fibrosis Foundation: Large disease-focused foundation that funded foundational CF research and partnered with Vertex to develop transformative therapies, generating substantial royalty revenues. A scaled-up version of Grace Science's intended research-to-treatment translation model, though operating at far greater scale and financial footprint.
  • National Organization for Rare Disorders (NORD): Umbrella advocacy organization for rare diseases in the US, providing patient assistance programs and policy advocacy. Comparable in rare disease mission space and policy influence but operates across many conditions rather than a single disease.

Emerging players

  • RARE-X: Nonprofit data platform focused on building federated patient registries for rare diseases. Comparable to Grace Science's patient registry initiative but operates as an infrastructure platform across many conditions rather than for a single disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Grace Science Foundation social profiles

Digital presence

Grace Science Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grace Science Foundation leadership team

Management profile

Number of profiles

Profiles4 records

Grace Science Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grace Science Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grace Science Foundation

What does Grace Science Foundation do?

Grace Science Foundation is a nonprofit medical research foundation that coordinates and funds a global research network of scientists and clinicians to find treatments and a cure for NGLY1 Deficiency, an ultra-rare genetic disorder. It operates an NGLY1 Patient Registry and natural history study, supports roughly 75 scientists across 20 medical centers in 5 countries, and bridges basic discovery to therapeutic development via a translational entity (Grace Science LLC) co-founded with Nobel Laureate Dr. Carolyn Bertozzi. The foundation is funded entirely through donations, with a stated commitment that 100% of contributions go directly to research.

Is Grace Science Foundation a public or private company?

Grace Science Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Grace Science Foundation founded?

Grace Science Foundation was founded in 2013. It employs 1 to 10 people.

Where is Grace Science Foundation based?

Grace Science Foundation is headquartered in San Francisco, United States, in the North America region.

How does Grace Science Foundation make money?

One revenue line is on record: donations and Charitable Contributions.

Who are Grace Science Foundation's main competitors?

Direct peers on record are Cure SMA, Chordoma Foundation, Parent Project Muscular Dystrophy (PPMD), Alex's Lemonade Stand Foundation, cureSanfilippo Foundation and Foundation for Prader-Willi Research. Broad incumbents are Global Genes, Cystic Fibrosis Foundation and National Organization for Rare Disorders (NORD). RARE-X is listed as an emerging player.

Does Grace Science Foundation have an API?

No public API is recorded for Grace Science Foundation.

What industry is Grace Science Foundation in?

Grace Science Foundation's product category is Rare Disease Research Foundation. Its primary akta.pro industry code is BPAGAKAI, Research & Science Grantmaking Foundations, with a secondary code of BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRare Disease Foundation Announces "Take Action" PlatformThe Grace Science Foundation launched a 'Take Action' platform to support and synchronize private fundraising efforts for NGLY1 Deficiency, a rare genetic disorder affecting only 49 known living patients. The platform was inspired by numerous grassroots fundraising initiatives by affected families, including a coastal adventure tourism business in Delaware that offers free beach wheelchairs in exchange for donations. Unlike popular fundraising platforms, GSF does not deduct processing fees, ensuring all proceeds go directly to rare disease research.PR NewswireRare Disease Foundation Announces First Global RegistryThe Grace Science Foundation announced the creation of the world's first NGLY1 Deficiency registry to support medical research into this rare genetic disorder. The registry currently contains data on 36 patients and has been utilized by researchers, including Dr. Carolyn Bertozzi at Stanford University, to accelerate therapy development.PR NewswireParents of Kids with Rare Disease Lead Urgent Push for CureThe Grace Science Foundation announced the formation of a global Family Advisory Board to empower families of patients with NGLY1 Deficiency in the search for a cure. The board comprises 20 members from nine countries, including the United States, India, and Germany, to facilitate collaboration and provide patient data to researchers.PR NewswirePerlara PBC Announces Patient Advocacy Group PartnershipsPerlara PBC announced two PerlQuest partnerships with the California-based Grace Science Foundation and the Arizona-based Wylder Nation Foundation to fund drug discovery research for NGLY1 Deficiency and Niemann-Pick Type A respectively. The patient advocacy groups will directly fund the research collaborations and receive joint ownership of the resulting data and inventions. The announcement builds on Perlara's previous commercial deal with Novartis for three lysosomal storage disorders.